Meeting
2019 Genitourinary Cancers Symposium
Apalutamide (APA) or enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (CRPC): A systematic review and network meta-analysis of randomized clinical trials (RCTs).
Authors
Irbaz Bin Riaz
Mayo Clinic, Rochester, MN
Irbaz Bin Riaz , Sandipan Bhattacharjee , Saad Malik , Thanh P. Ho , Qurat Ul Ain Riaz Sipra , Muhammad Zain Farooq , Safi U. Khan , M. Hassan Murad , Manish Kohli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 263)
DOI
10.1200/JCO.2019.37.7_suppl.263
Abstract #
263
Poster Bd #
L20
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
A systematic review and network meta-analysis of FDA approved treatment options in men with nonmetastatic, castration-resistant prostate cancer (M0CRPC).
First Author: Irbaz Bin Riaz
Poster
2021 Genitourinary Cancers Symposium
Network meta-analysis (NMA) comparing the efficacy of enzalutamide versus apalutamide, darolutamide, and bicalutamide for treatment of nonmetastatic (nm) castration-resistant prostate cancer (CRPC).
First Author: Tomasz M. Beer
Poster
2020 ASCO Virtual Scientific Program
Safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): Matching-adjusted indirect comparisons.
First Author: Shan Jiang
Poster
2020 Genitourinary Cancers Symposium
Novel androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer: A network meta-analysis.
First Author: Amanda Elizabeth Hird